High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma

Background & Aims: We elucidated the clinical and immunologic implications of serum IL-6 levels in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Ate/Bev). Methods: We prospectively enrolled 165 patients with unresectable HCC (discovery cohor...

Description complète

Détails bibliographiques

Auteurs principaux:	Hannah Yang, Beodeul Kang, Yeonjung Ha, Sung Hwan Lee, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Gwangil Kim, Sanghoon Jung, Sun Young Rha, Vincent E. Gaillard, Jaekyung Cheon, Chan Kim, Hong Jae Chon
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2023-04-01
Collection:	JHEP Reports
Sujets:	Hepatocellular carcinoma IL-6 Atezolizumab Bevacizumab Immunotherapy
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2589555923000034
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!